LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Search

Repligen Corp

Ouvert

SecteurSoins de santé

164.29 0.9

Résumé

Variation du prix de l'action

24h

Actuel

Min

160.86

Max

166.86

Chiffres clés

By Trading Economics

Revenu

45K

15M

Ventes

6.4M

189M

P/E

Moyenne du Secteur

8,317.501

80.03

BPA

0.46

Marge bénéficiaire

7.898

Employés

1,778

EBITDA

2.9M

47M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+8.82% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

6.6M

9.4B

Ouverture précédente

163.39

Clôture précédente

164.29

Sentiment de l'Actualité

By Acuity

23%

77%

53 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Repligen Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

19 nov. 2025, 23:36 UTC

Actions en Tendance

Stocks to Watch: Nvidia, Kulicke & Soffa, Regeneron

Comparaison

Variation de prix

Repligen Corp prévision

Objectif de Prix

By TipRanks

8.82% hausse

Prévisions sur 12 Mois

Moyen 181.2 USD  8.82%

Haut 220 USD

Bas 135 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

14 ratings

10

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

125.31 / 140.7Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Strong Bearish Evidence

Sentiment

By Acuity

53 / 374Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
help-icon Live chat